Acutus Story

<div class='circular--portrait' style='background:#82ADFD;color: #ffffff;font-size:4em;'>AM</div>
AFIB -- USA Stock  

USD 23.66  3.63  13.30%

As many rational traders are trying to avoid healthcare space, it makes sense to go over Acutus Medical a little further and understand how it stands against ENCISION INC and other similar entities. We are going to analyze some of the competitive aspects of both Acutus and ENCISION.
Published over three months ago
View all stories for Acutus Medical | View All Stories
Are ENCISION (OTC:ECIA) investors switching to Acutus (NASDAQ:AFIB)?
By analyzing existing basic indicators between Acutus Medical and ENCISION, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in ENCISION with a short position in Acutus Medical. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Acutus suggests not a very effective usage of assets in September.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Acutus or Establishment is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Acutus Medical's Liquidity

Acutus Medical financial leverage refers to using borrowed capital as a funding source to finance Acutus Medical ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Acutus Medical financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Acutus Medical's total debt and its cash.

Correlation Between Acutus and Establishment Labs

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Acutus Medical together with similar or unrelated positions with a negative correlation. For example, you can also add Establishment Labs to your portfolio. If Establishment Labs is not perfectly correlated to Acutus Medical it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Acutus Medical for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down. Please check pair correlation details between AFIB and ESTA for more information.

Purchase by Flynn James E of 944444 shares of Acutus Medical

Legal trades by Acutus Medical insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Acutus insider trading alert for perchase of common stock by Flynn James E, the corporate stakeholder, on 15th of August 2020. This event was filed by Acutus Medical Inc with SEC on 2020-08-12. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Detailed Outlook On Acutus Medical

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Now, let's check Acutus Medical revenue. Based on the latest financial disclosure, Acutus Medical reported 3.63 M of revenue. This is 99.95% lower than that of the Healthcare sector and 99.86% lower than that of the Medical Devices industry. The revenue for all United States stocks is 99.96% higher than that of the company. As for ENCISION INC we see revenue of 7.09 M, which is 99.72% lower than that of the Medical Devices

2.6 B
AFIB3.63 Million0.14
Sector2.55 Billion99.58
ECIA7.09 Million0.28

Will Acutus Medical growth be reasonable after the rise?

Current total risk alpha is at 0.59. Acutus Medical shows above-average downside volatility for the selected time horizon. We advise investors to inspect Acutus Medical further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Acutus Medical future alpha.

Our Bottom Line On Acutus Medical

Whereas many other companies within the medical devices industry are still a little expensive, even after the recent corrections, Acutus Medical may offer a potential longer-term growth to investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither acquire new shares of Acutus nor short your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Acutus Medical.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Acutus Medical. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to